Long-Acting GHRH Analog · COA Verified
For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.
For Research Purposes Only. Not approved for human consumption.
CJC-1295 with DAC is engineered for extended half-life (~6-8 days) through covalent albumin binding via its maleimidoproprionic acid group. This creates a sustained depot effect maintaining GHRH receptor stimulation over an extended period — ideal for research protocols requiring chronic, sustained GH elevation with less frequent administration than the No DAC version.
Q: How does albumin binding extend half-life?
A: The DAC maleimide group reacts with a free cysteine on serum albumin, tethering the peptide to the most abundant plasma protein and drastically slowing clearance rate.
Q: Can CJC-1295 DAC still be combined with GHRPs?
A: Yes. DAC provides sustained GHRH receptor background; GHRPs provide pulsatile ghrelin receptor stimulation. Many researchers combine both for comprehensive GH axis studies.
Q: What is the research advantage of long-acting GHRH?
A: Allows longitudinal studies of downstream GH/IGF-1 effects without frequent dosing — more practical for extended study designs.
Related Research: CJC-1295 No DAC | Ipamorelin | Sermorelin Research Peptide
For laboratory research use only. Not for human consumption. Not evaluated by the FDA.
